Emerging treatment options for myelofibrosis: focus on pacritinib

Myelofibrosis (MF) is a myeloid malignancy associated with a heavy symptomatic burden that decreases quality of life and presents a risk for leukemic transformation. While there are limited curative treatments, the recent discovery of the Janus kinase/signal transducer and activator of transcription...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Vivian, Weissman, Ashley, O’Connell, Casey Lee, Mehrvar, Azim, Akhtari, Mojtaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863690/
https://www.ncbi.nlm.nih.gov/pubmed/27226728
http://dx.doi.org/10.2147/OTT.S93875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863690/
https://www.ncbi.nlm.nih.gov/pubmed/27226728
http://dx.doi.org/10.2147/OTT.S93875

Ejemplares similares